<DOC>
	<DOCNO>NCT01385800</DOCNO>
	<brief_summary>Grass pollen allergen recognise major cause allergic disease humans animal . Worldwide , least 40 % allergic patient sensitise grass pollen allergens 50-90 % hayfever seasonal allergy sufferer allergic grass pollen . ToleroMune Grass novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment grass allergy . This study look efficacy , safety tolerability three dos ToleroMune Grass grass allergic subject follow challenge grass Environmental Exposure Unit ( EEU ) .</brief_summary>
	<brief_title>ToleroMune Grass Exposure Unit Study</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled , parallel group study evaluate safety tolerability ToleroMune Grass grass allergic subject allergic rhinoconjunctivitis . The efficacy ToleroMune Grass explore subject use EEU ( Environmental Exposure Unit ) . The study consist 3 study period . In Period 1 , Screening perform maximum 16 week randomisation may consist one two visit clinic , Investigator 's discretion . Baseline Challenge consist 4 visit EEU least 3 day randomisation . In Period 2 , subject cohort comply inclusion/exclusion criterion randomise one four group receive treatment every 2 week ( Â±2 day ) 14 week . In Period 3 , Post Treatment Challenge consist 4 visit EEU 25 week first administration treatment period assessment perform identical baseline challenge . Follow-up conduct 3-10 day PTC .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Inclusion criterion Male female , age 1865 year . Minimum 2year document history rhinoconjunctivitis exposure grass . Positive skin prick test grass allergen . Minimum qualify rhinoconjunctivitis symptom score Exclusion criterion History asthma . A history anaphylaxis grassallergen . Subjects FEV1 &lt; 80 % predict . Subjects tolerate baseline challenge EEU . Subjects administration epinephrine contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . A history severe drug allergy , severe angioedema anaphylactic reaction food . A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Grass allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Environmental Exposure Unit</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune Grass</keyword>
</DOC>